Effectiveness and safety of oral orforglipron in Japanese people with obesity

Orforglipron has demonstrated bodyweight reduction and cardiometabolic benefits in adults with obesity.

• Orforglipron is a small-molecule, non-peptide drug that activates GLP-1 receptors.
• The drug has shown efficacy in reducing body weight in phase 3 trials.
• Cardiometabolic benefits have been observed alongside weight reduction.
• The study focuses on assessing orforglipron's effects specifically in Japanese adults with obesity.

Simplified